Kinase News and Research

RSS

Researchers focus on phosphoinositide 3-kinase pathway in cancer research

Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN ).

5 Dec 2008

Advance in K-Ras-mutated cancer research

A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches.

30 Nov 2008

Discovery of novel approach to suppress prostate cancer progression

Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

24 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

Light drinking has certain health benefits, researchers look at why

While the physiological damage and social havoc created by alcohol abuse and dependency are well-known, it is also true that light-to-moderate drinking has certain health benefits.

20 Nov 2008

KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

New imaging technique tracks cancer-killing cells over prolonged period

Coaxing a patient's own cells to hunt down and tackle infected or diseased cells is a promising therapeutic approach for many disorders.

18 Nov 2008

Kinase inhibitors may offer new therapeutic approach for treatment of type 1 diabetes

Researchers at the University of California, San Francisco have reported that two common cancer drugs have been used to block and reverse type 1 diabetes in mice.

18 Nov 2008

Two common cancer drugs prevent, reverse type 1 diabetes

Two common cancer drugs have been shown to both prevent and reverse type 1 diabetes in a mouse model of the disease, according to research conducted at the University of California, San Francisco.

18 Nov 2008

Study helps clarify role of vitamin D in cancer therapy

A colon cancer cell isn't a lost cause. Vitamin D can tame the rogue cell by adjusting everything from its gene expression to its cytoskeleton.

17 Nov 2008

Scientists find a trigger to aggressive bowel cancer

CANCER RESEARCH UK scientists have shown how bowel cancer can become aggressive, according to research published in Nature Genetics.

17 Nov 2008

'Intelligent' cancer drug development boosts success rates

A new era of intelligent cancer drug development has spurred a leap in the proportion of drugs reaching patients, according to a study by Cancer Research UK scientists published in Nature Reviews Drug Discovery.

17 Nov 2008

PEA-15 protein points to potential targeted approach for ovarian cancer

A protein known to inhibit the growth of ovarian cancer works in part by forcing cancer cells to eat themselves until they die, researchers at The University of Texas M. D. Anderson Cancer Center report in the Nov. 15 issue of Cancer Research .

16 Nov 2008

Cigarette smoke may reshape the left ventricle

Prolonged exposure to cigarette smoke can increase levels of the stress hormone norepinephrine and enzymes in the heart that have the potential to reshape the left ventricle, according to new research at the University of Illinois at Chicago.

16 Nov 2008

Researchers uncover beneficial mechanism of the helpful "Dr. Jekyll" side of the Cdk5 protein

Researchers at UT Southwestern Medical Center have uncovered new insights into the "Dr. Jekyll and Mr. Hyde" nature of a protein that stimulates stem-cell maturation in the brain but, paradoxically, can also lead to nerve-cell damage.

12 Nov 2008

Does HBV infection induce acute cellular DNA damage?

Eukaryotic cells employ multiple strategies of checkpoint signaling and DNA repair mechanisms to monitor and repair damaged DNA.

11 Nov 2008

Protein can nurture or devastate brain cells, depending on its 'friends,' UT Southwestern researchers find

11 Nov 2008

Alteration of a gene causes neuroblastoma

Olivier Delattre's team (Inserm Unit 830 "Genetics and Biology of Cancer") of the Institut Curie reveal in an article in the 16 October issue of Nature that alteration of the ALK gene is closely associated with the most frequent solid extracerebral tumor in children-neuroblastoma. By studying the familial forms of this tumor, the researchers also conclude that ALK is a gene that predisposes to neuroblastoma.

7 Nov 2008

Apelin hormone shows promise as target for managing insulin resistance and type 2 diabetes

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice.

5 Nov 2008